Nonetheless, although results are encouraging for PI3Kδ inhibitors in some hematopoietic tumors [ 14], the results from a recent clinical trial using buparlisib (a pan-PI3K inhibitor) for NSCLC patients (preselected to exhibit PI3K pathway activation) showed that only 3% (SQCC and non-squamous) responded by reducing tumor size [16, 17]. This evidence concerns the gene PIK3CD and neoplasm.